Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.

Latest From Cathy Kelly

Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes

Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.

Reimbursement Medicare

Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates

First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.

Biosimilars Commercial

Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use

A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.

Reimbursement Medicaid

MACPAC ‘Undeterred’ By Lukewarm Reception Of Accelerated Drug Approval Recommendation

Executive director Schwartz suggests Congress may turn its attention to the advisory commission’s proposal to revise Medicaid coverage for drugs approved under the accelerated approval pathway in the next year or two.

Medicaid Gene Therapy

Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products

Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.

Commercial Advertising, Marketing & Sales

Pfizer’s ‘Industry First’ Warranty Program For Xalkori Available To Medicare Part D Patients

Pilot program offers Part D beneficiaries an alternative to manufacturer assistance in the form of copay coupons, which are prohibited in government-sponsored health plans. New program also available to commercial insurance and cash-paying patients.

Medicare Reimbursement
See All
UsernamePublicRestriction

Register